65,437 trials
Advanced Epithelial Ovarian · Recurrent Epithelial Ovarian · Fallopian Tube
Primary: Overall Response Rate — 1.7 percentage of participants with response
Sensorineural Hearing Loss · Noise Induced Hearing Loss · Sudden Sensorineural Hearing Loss
Primary: Word Recognition in Quiet — 23.8; 16.7; 15.8; 18.8 Percent — p=0.068
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
SARS-CoV-2
Primary: Number of Participants With COVID 19 Severity — 5; 4; 2; 0 Participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Graft Rejection — 3 Participants
Head and Neck Cancer
Primary: Proportion of Caregivers Who Agree to Participate — 2.1 participants per month
Obesity
Primary: Change in 48h-fecal Bile Acid Excretion (μmol/L) Between Baseline and High Fat Diet — 543; 344 (μmol/L)/48 hour
Family Members · Post Intensive Care Unit Syndrome · Post Traumatic Stress Disorder
Primary: Symptoms of Post-Traumatic Stress Disorder (PTSD) Initial — 27.9 score on a scale
Adhesive Capsulitis · Adhesive Capsulitis of Unspecified Shoulder · Frozen Shoulder
Primary: Change in American Shoulder and Elbow Score (ASES)
Accidental Falls/Prevention and Control
Primary: Number of High-risk Residents According to the FRAiL Model — 46 Participants
Clostridium Difficile Infection
Primary: Recurrence of CDI up to 8 Weeks — 11; 37 Participants — p=<0.001
Visual Acuity
Primary: High Luminance High Contrast Monocular Visual Acuity (LogMAR) — -0.126; -0.028 logMAR
Weight Gain · Obesity
Primary: Change in Weight From Baseline — -1.4; -0.8 kilograms
Scoliosis · Pain
Primary: Post-operative Opioid Consumption (mg/kg) — 0.267; 0.340 mg/kg — p=<0.05
Eosinophilic Esophagitis
Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001